SWAV — Shockwave Medical Income Statement
0.000.00%
Last trade - 00:00- $12.25bn
- $12.00bn
- $730.23m
Annual income statement for Shockwave Medical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 42.9 | 67.8 | 237 | 490 | 730 |
| Cost of Revenue | |||||
| Gross Profit | 25.8 | 46.8 | 196 | 425 | 635 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 94.8 | 133 | 238 | 366 | 571 |
| Operating Profit | -51.8 | -65.7 | -0.871 | 124 | 159 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -51 | -65.6 | -8.84 | 121 | 174 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -51.1 | -65.7 | -9.14 | 216 | 147 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -51.1 | -65.7 | -9.14 | 216 | 147 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -51.1 | -65.7 | -9.14 | 216 | 147 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.14 | -1.99 | -0.26 | 5.7 | 3.85 |